{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:12:10Z","timestamp":1789668730025,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002553","name":"Aid for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","award":["QoC 004"],"award-info":[{"award-number":["QoC 004"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.semarthrit.2026.152975","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:32:55Z","timestamp":1775665975000},"page":"152975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis"],"prefix":"10.1016","volume":"78","author":[{"given":"Medha L.","family":"Soowamber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Sanchez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel Zehra","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Camellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Hendry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaz A","family":"Kermani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader A","family":"Khalidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Mahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L","family":"Matteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Maz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Monach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M","family":"Villiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-2076","authenticated-orcid":false,"given":"Zahi","family":"Touma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2026.152975_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large vessel vasculitis","volume":"7","author":"Pugh","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152975_bib0002","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.berh.2018.09.001","article-title":"Update on the epidemiology, risk factors, and outcomes of systemic vasculitides","volume":"32","author":"Berti","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152975_bib0003","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.rdc.2023.03.005","article-title":"Giant Cell Arteritis and Polymyalgia Rheumatica: Treatment Approaches and New Targets","volume":"49","author":"Nepal","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152975_bib0004","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/BOR.0000000000001029","article-title":"Current management of giant cell arteritis and its complications","volume":"36","author":"Galli","year":"2024","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152975_bib0005","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/ard-2022-223751","article-title":"What is a response in randomised controlled trials in giant cell arteritis?","volume":"82","author":"Dejaco","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152975_bib0006","doi-asserted-by":"crossref","first-page":"e003233","DOI":"10.1136\/rmdopen-2023-003233","article-title":"Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force","volume":"9","author":"Sanchez-Alvarez","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152975_bib0007","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152975_bib0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152975_bib0009","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.152975_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304651","article-title":"Delphi studies in social and health sciences\u2014Recommendations for an interdisciplinary standardized reporting (DELPHISTAR). Results of a delphi study","volume":"19","author":"Niederberger","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2026.152975_bib0011","unstructured":"Vasculitis Clinical Research Consortium (VCRC). Vasculitis Clinical Research Consortium. https:\/\/vcrc.rarediseasesnetwork.org\/."},{"key":"10.1016\/j.semarthrit.2026.152975_bib0012","unstructured":"European Vasculitis Society (EUVAS). European Vasculitis Society. https:\/\/vasculitis.org\/."},{"key":"10.1016\/j.semarthrit.2026.152975_bib0013","unstructured":"Canadian Vasculitis Research Network (CanVasc). Canadian Vasculitis Research Network website. https:\/\/canvasc.ca\/."},{"key":"10.1016\/j.semarthrit.2026.152975_bib0014","unstructured":"Vasculitis Patient-Powered Research Network (VPPRN). Vasculitis Patient-Powered Research Network. https:\/\/vasculitisfoundation.org\/treatments-research\/patient-powered-research\/."},{"key":"10.1016\/j.semarthrit.2026.152975_bib0016","unstructured":"PMRGCAuk. PMRGCAuk. https:\/\/pmrgca.org.uk\/."},{"key":"10.1016\/j.semarthrit.2026.152975_bib0018","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jclinepi.2020.09.034","article-title":"Two different invitation approaches for consecutive rounds of a delphi survey led to comparable final outcome","volume":"129","author":"Boel","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152975_bib0019","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152975_bib0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152975_bib0021","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152975_bib0022","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152975_bib0023","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.152975_bib0024","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.152975_bib0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"10031","key":"10.1016\/j.semarthrit.2026.152975_bib0026","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152975_bib0027","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40744-020-00227-2","article-title":"A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of sirukumab in the treatment of giant cell arteritis","volume":"7","author":"Schmidt","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152975_bib0028","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152975_bib0029","article-title":"Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"10","author":"Rohde","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152975_bib0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00296-023-05508-x","article-title":"Trends in health care of patients with vasculitides, including giant cell arteritis, takayasu arteritis, ANCA-associated vasculitis and beh\u00e7et's disease: cross-sectional data of the german national database 2007-2021","volume":"44","author":"Henes","year":"2024","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152975_bib0031","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/acr.22237","volume":"66","author":"Castrej\u00f3n","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2026.152975_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108769","article-title":"When national drug surveys \u201ctake too long\u201d: an examination of who is at risk for survey fatigue","volume":"225","author":"Le","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152975_bib0033","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1177\/0013164415627349","article-title":"Survey satisficing inflates reliability and validity measures","volume":"76","author":"Hamby","year":"2016","journal-title":"Educ Psychol Meas"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152975_bib0034","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/art.22003","article-title":"Development of classification and response criteria for rheumatic diseases","volume":"55","author":"Singh","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152975_bib0035","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/ard-2023-224543","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update","volume":"83","author":"Dejaco","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152975_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11797","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography to monitor disease activity in patients with giant cell arteritis on tocilizumab","volume":"7","author":"Quinn","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152975_bib0037","article-title":"Vascular ultrasound as a follow-up tool in patients with giant cell arteritis: a prospective observational cohort study","volume":"11","author":"Haaversen","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152975_bib0038","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/biom15111505","article-title":"The Role of Imaging in Monitoring Large Vessel Vasculitis: A Comprehensive Review","volume":"15","author":"Sopa","year":"2025","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152975_bib0039","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","article-title":"Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients","volume":"84","author":"Gonzalez-Gay","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152975_bib0040","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11606-024-09141-7","article-title":"Atypical Signs and Symptoms of Giant Cell Arteritis: A Systematic Review","volume":"40","author":"Sverdlichenko","year":"2025","journal-title":"J Gen Intern Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152975_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201378","article-title":"Recruiting and retaining participants in e-Delphi surveys for core outcome set development: evaluating the COMiT'ID study","volume":"13","author":"Hall","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152975_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000393","article-title":"Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies","volume":"8","author":"Sinha","year":"2011","journal-title":"PLoS Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:58:14Z","timestamp":1789667894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S0049017226000648"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152975","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152975"}}